You just read:

Enteris BioPharma's "Feasibility to Licensing" Partner, Cara Therapeutics, Advances Peptelligence™-Engineered CR845 into Phase 2b Clinical Trial in Chronic Pain

News provided by

Enteris BioPharma, Inc.

19 Sep, 2016, 09:15 ET